beta
Trial Radar AI
One study matched filter criteria
Card View
Back to Search

CGM Boosted by Artificial Intelligence for Better Glycaemic Control in T2 Diabetes (MAGIC-T2D) 440 Travel Reimbursed Real-World Evidence Observational

Active, not recruiting
Clinical Trial NCT07064499 (MAGIC-T2D) is an observational study for Type 2 Diabetes that is active, not recruiting. It started on 15 December 2023 with plans to enroll 440 participants. Led by Erasme University Hospital, it is expected to complete by 31 July 2027. The latest data from ClinicalTrials.gov was last updated on 11 August 2025.
Brief Summary
Title: CGM Boosted by Artificial Intelligence for better glycaemic control in T2 Diabetes : a real-life multicenter observational study in Belgium - MAGIC-T2D

Background: In Belgium, since May 2023, reimbursement for continuous glucose monitoring systems has been extended to people with type 2 diabetes taking multiple injections of insulin. Despite the results of previous studies, the impact of this technology in te...

Show More
Official Title

CGM Boosted by Artificial Intelligence for Better Glycaemic Control in T2 Diabetes: a Real-life Multicentre Observational Study in Belgium.

Conditions
Type 2 Diabetes
Publications
Scientific articles and research papers published about this clinical trial:
Other Study IDs
  • MAGIC-T2D
  • SRB2021470
NCT ID Number
NCT07064499
Start Date (Actual)
2023-12-15
Last Update Posted
2025-08-11
Completion Date (Estimated)
2027-07-31
Enrollment (Estimated)
440
Study Type
Observational
Status
Active, not recruiting
Keywords
Evolution of Type 2 Diabetes Following CGM Introduction
Progression of Type 2 Diabetes Across Endotypes Following CGM Initiation
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Evolution of TIR (glucose 70-180 mg/dl) over a 12-month period after initiation of CGM in patients with T2D treated with MDI regimens.
From registration to end of 1-year follow-up
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Evolution of Hba1c over a 12-month period after initiation of CGM
From registration to end of 1-year follow-up
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  • Type 2 diabetes on MDI and starting CGM

  • Dialysis
  • Treatment that raises blood sugar levels (corticosteroids, etc.)
  • Secondary and type 1 diabetes
  • Patient not able to sign the Informed Consent
Erasme University Hospital logoErasme University Hospital
No contact data.
1 Study Locations in 1 Countries
HUB-Hôpital ERASME, Brussels, 7850, Belgium